AOD-9604 in Lisle — Fat Loss Peptide Research Guide
AOD-9604 research guide for Lisle. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
AOD-9604 isn't stocked on pharmacy shelves in Lisle or anywhere else for that matter — this is a specialist compound distributed through a dedicated online market. The practical advantage of this online-only market is that serious vendors compete aggressively on their analytical documentation, giving researchers access to better quality signals than any local market ever offers. Separating quality AOD-9604 from the rest of the market comes down to three things: an HPLC chromatogram showing ≥98% purity, mass spec data confirming the correct molecular weight, and a batch-specific endotoxin panel. The sections below cover what Lisle researchers need to know about finding, evaluating, and storing AOD-9604 for legitimate research applications.
AOD-9604: What the Research Shows
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Lisle researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
How to Source AOD-9604 — Vendor Guide
Quality AOD-9604 sourcing begins with a useful first test: does this vendor share complete COA data without being asked? Suppliers that publish proactively are signalling genuine quality commitment. The HPLC chromatogram is the most important document in the COA: it should show a clear dominant peak representing AOD-9604, with minimal secondary peaks representing impurities — purity should be 98% or higher. Positive vendor signals beyond COA quality: established track record of at least two years, knowledgeable support capable of explaining COA data, and cold chain packaging that protects product integrity. Store lyophilised AOD-9604 at minus 20 degrees Celsius until ready to use; reconstitute only the quantity required for your immediate research and store the rest at −20°C.
Order AOD-9604 — ships to Lisle
COA-verified · International tracking · Research grade
All use of AOD-9604 in Lisle or anywhere must be research use only — this compound is not approved for therapeutic human application, and all handling should adhere to research compound handling standards. Lyophilised AOD-9604 should be stored frozen (−20°C) immediately upon receipt; avoid repeatedly thawing and refreezing reconstituted peptide by dividing into single-dose aliquots before freezing. Endotoxin testing in the AOD-9604 COA is absolutely required — gram-negative bacterial endotoxins can trigger severe inflammatory responses at very low concentrations, and no pricing advantage justifies skipping this verification. Researchers using AOD-9604 alongside other research compounds should check the research literature for any reported interactions before beginning combination research.
Frequently Asked Questions
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
